Literature DB >> 15759068

Chemotherapy-induced peripheral neuropathy.

Terri Armstrong1, Lois Almadrones, Mark R Gilbert.   

Abstract

PURPOSE/
OBJECTIVES: To review the literature documenting the scope, treatment, and prevention of chemotherapy-induced neuropathy. DATA SOURCES: Published abstracts, primary research literature, and textbook chapters. DATA SYNTHESIS: Recent improvements in the management of other treatment-related toxicities have led to peripheral neuropathy becoming a dose-limiting toxicity of commonly used chemotherapeutic groups such as platinols, vinca alkaloids, and taxanes.
CONCLUSIONS: The nervous system has not been the focus of education or training for oncology nurses. Therefore, nurses' ability to educate patients regarding this aspect of their condition has been limited. IMPLICATIONS FOR NURSING: With its significant impact on quality of life, peripheral neuropathy treatment and prevention are important components in the care of patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15759068     DOI: 10.1188/05.ONF.305-311

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  25 in total

1.  Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency.

Authors:  Janet M Schloss; Maree Colosimo; Caroline Airey; Luis Vitetta
Journal:  Support Care Cancer       Date:  2015-04-12       Impact factor: 3.603

2.  Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma.

Authors:  Byung-Jo Kim; Ha-Rim Park; Hak Jae Roh; Du-Shin Jeong; Byung Soo Kim; Kun-Woo Park; S Charles Cho; Yuen T So; Sung Yong Oh; Seok Jin Kim
Journal:  Qual Life Res       Date:  2010-05-05       Impact factor: 4.147

3.  A Hyperresponsive HPA Axis May Confer Resilience Against Persistent Paclitaxel-Induced Mechanical Hypersensitivity.

Authors:  Sharon L Kozachik; Gayle G Page
Journal:  Biol Res Nurs       Date:  2015-10-27       Impact factor: 2.522

4.  Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.

Authors:  Rhonda J Moore; Hunter Groninger
Journal:  Cureus       Date:  2013-06-14

5.  Electroacupuncture alleviates chemotherapy-induced pain through inhibiting phosphorylation of spinal CaMKII in rats.

Authors:  Y Zhang; A Li; J Xin; K Ren; B M Berman; L Lao; R-X Zhang
Journal:  Eur J Pain       Date:  2017-10-16       Impact factor: 3.931

6.  The Experience of Chemotherapy-Induced Peripheral Neuropathy Among Childhood Cancer Survivors.

Authors:  Caroline Mohrmann
Journal:  J Pediatr Oncol Nurs       Date:  2019-05-05       Impact factor: 1.636

7.  A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).

Authors:  Janet M Schloss; Maree Colosimo; Caroline Airey; Paul Masci; Anthony W Linnane; Luis Vitetta
Journal:  Support Care Cancer       Date:  2016-09-09       Impact factor: 3.603

8.  The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.

Authors:  Ilaria Cervellini; Ezia Bello; Roberta Frapolli; Carla Porretta-Serapiglia; Norberto Oggioni; Annalisa Canta; Raffaella Lombardi; Francesca Camozzi; Ilaria Roglio; Roberto Cosimo Melcangi; Maurizio D'incalci; Giuseppe Lauria; Pietro Ghezzi; Guido Cavaletti; Roberto Bianchi
Journal:  Neurotox Res       Date:  2009-10-30       Impact factor: 3.911

9.  Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Authors:  Joseph D Tariman; Ginger Love; Emily McCullagh; Stacey Sandifer
Journal:  Clin J Oncol Nurs       Date:  2008-06       Impact factor: 1.027

10.  Prevalence and treatment patterns of physical impairments in patients with metastatic breast cancer.

Authors:  Andrea L Cheville; Andrea B Troxel; Jeffrey R Basford; Alice B Kornblith
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.